search
Back to results

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Abacavir sulfate
Sponsored by
Glaxo Wellcome
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring Drug Interactions, Antiviral Agents, Ethanol, abacavir

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Concurrent Medication: Allowed: Local treatment for Kaposi's sarcoma. Prophylactic treatment for opportunistic infections. Patients must have: HIV-1 infection. CD4+ lymphocyte count >= 200 cells/microliter within 14 days prior to study drug administration. No active diagnosis of AIDS (other than visceral Kaposi's sarcoma) according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition. Prior Medication: Allowed: Local treatment for Kaposi's sarcoma. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Malabsorption syndrome or other GI dysfunction which may interfere with drug absorption. Concurrent Medication: Excluded: Medications that cannot be withheld for 48 hours (24 hours for antiretrovirals) prior to study drug administration and until 12 hours after study drug administration on each dosing day. Immunomodulators, such as systemic corticosteroids, interleukins and interferons. Cytotoxic chemotherapeutic agents. Acute treatment for opportunistic infections. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior conditions are excluded: Documented history of alcoholism. History of clinically relevant hepatitis or pancreatitis within 6 months prior to study drug administration. History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside analogs. Participation in another research study within the past month. Prior Medication: Excluded: Cytotoxic chemotherapeutic agents within six weeks prior to study drug administration. Immunomodulating agents within six weeks prior to study drug administration. Treatment with the following within 2 weeks prior to study drug administration: acyclovir, carbamazepine, chloramphenicol, ganciclovir, phenytoin, rifampin, sodium valproate, or valacyclovir. Prior Treatment: Excluded: Radiation therapy within 6 weeks prior to study drug administration. 1. Regular weekly alcohol intake of more than 21 units (a unit is equal to 1/2 pint beer or 1 glass of wine or 1 oz of liquor). Recent change in normal pattern of alcohol usage (e.g., prolonged use followed by > one month abstinence). Total abstinence from alcohol use. Positive breath alcohol test upon arrival at the study center prior to any dosing day.

Sites / Locations

  • PPD Development, Inc

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
June 23, 2005
Sponsor
Glaxo Wellcome
search

1. Study Identification

Unique Protocol Identification Number
NCT00002198
Brief Title
A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients
Official Title
A Study to Investigate Whether There is a Pharmacokinetic Interaction Between 1592U89 and Ethanol Following Their Co-Administration to HIV-Infected Subjects.
Study Type
Interventional

2. Study Status

Record Verification Date
August 1997
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Glaxo Wellcome

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to see how the body processes 1592U89 and ethanol (pure grain alcohol) when they are given together.
Detailed Description
Patients are randomized to one of the following three regimens: Regimen 1: 1592U89 alone. Regimen 2: pure grain alcohol diluted in orange juice. Regimen 3: 1592U89 plus pure grain alcohol diluted in orange juice. Treatment is administered weekly for 3 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
Drug Interactions, Antiviral Agents, Ethanol, abacavir

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Masking
None (Open Label)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Abacavir sulfate

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Local treatment for Kaposi's sarcoma. Prophylactic treatment for opportunistic infections. Patients must have: HIV-1 infection. CD4+ lymphocyte count >= 200 cells/microliter within 14 days prior to study drug administration. No active diagnosis of AIDS (other than visceral Kaposi's sarcoma) according to the 1993 Centers for Disease Control and Prevention (CDC) AIDS surveillance definition. Prior Medication: Allowed: Local treatment for Kaposi's sarcoma. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Malabsorption syndrome or other GI dysfunction which may interfere with drug absorption. Concurrent Medication: Excluded: Medications that cannot be withheld for 48 hours (24 hours for antiretrovirals) prior to study drug administration and until 12 hours after study drug administration on each dosing day. Immunomodulators, such as systemic corticosteroids, interleukins and interferons. Cytotoxic chemotherapeutic agents. Acute treatment for opportunistic infections. Concurrent Treatment: Excluded: Radiation therapy. Patients with the following prior conditions are excluded: Documented history of alcoholism. History of clinically relevant hepatitis or pancreatitis within 6 months prior to study drug administration. History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside analogs. Participation in another research study within the past month. Prior Medication: Excluded: Cytotoxic chemotherapeutic agents within six weeks prior to study drug administration. Immunomodulating agents within six weeks prior to study drug administration. Treatment with the following within 2 weeks prior to study drug administration: acyclovir, carbamazepine, chloramphenicol, ganciclovir, phenytoin, rifampin, sodium valproate, or valacyclovir. Prior Treatment: Excluded: Radiation therapy within 6 weeks prior to study drug administration. 1. Regular weekly alcohol intake of more than 21 units (a unit is equal to 1/2 pint beer or 1 glass of wine or 1 oz of liquor). Recent change in normal pattern of alcohol usage (e.g., prolonged use followed by > one month abstinence). Total abstinence from alcohol use. Positive breath alcohol test upon arrival at the study center prior to any dosing day.
Facility Information:
Facility Name
PPD Development, Inc
City
Wilmington
State/Province
North Carolina
ZIP/Postal Code
28412
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients

We'll reach out to this number within 24 hrs